Corrections and Clarifications by unknown
Correspondence
NTP, many have been considered but few
have been selected. Because many of the
chemicals evaluated by IARC and the NTP
are the same, although many are unique as
well, one cannot simply add numerical data
from these two sources without individual
comparisons. Unfortunately, neither orga-
nization lists the agents that were consid-
ered but not selected for formal review
because the available data are not consid-
ered adequate; that is, there may be no can-
cer data on a chemical, or the available data
are insufficient to meet either agency's crite-
ria for review.
Another issue posed by Lewis et al. (1)
concerns the value ofrodent bioassays. This
has been an ongoing debate for many years.
Some facts may be of interest. We know
that all known human carcinogens that
have been tested adequately in laboratory
rodents are also carcinogenic to animals
(2,4,6); for nearly 30 agents, the evidence of
carcinogenicty was first observed in animals,
ignored for the most part, and only subse-
quently detected in humans (7,8). These
studies have all been accomplished using
what some describe as the "maximum toler-
ated dose," which is at best operational ter-
minology that has been literally misapplied
and distorted, and is obsolete (9,10). A
more accurate term is "minimally toxic
dose" (MTD), or "minimally toxic expo-
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sure" (MTE), because when long-term
bioassays are conducted, one must be cer-
tain that some adverse effects of the chemi-
cal are occurring, or the time, resources,
and efforts will be wasted. Further, there is
little evidence to support a "high-dose only"
phenomenon in carcinogenesis. That is,
using an MTD concept ofexposure cannot
"make" a chemical a carcinogen when it is a
noncarcinogen (1]).
I agree with Lewis et al. (1) that
in the safety evaluation ofchemicals, we should be
cauttiouIs in extrapolating results from experimental
animal Imnodels to humans.
Conversely, I do not agree that we should
ignore long-term bioassay results or delay
preventative strategies until we have defini-
tive mechanistic data, such as, for example,
species differences and similarities in
cytochrome P450 isoform carcinogen
metabolic information, proposed by Lewis
et al. (1). This does not mean such infor-
mation will not be useful to the overall par-
adigm of quantifying carcinogenic risk in
humans, but that equal cautions must be
recognized in considering another in a
lengthy line of mechanistic discoveries.
This information may only modify or
extend quantitative estimates of risk. On
this issue, the distribution ofthese enzymes
may be most useful for evaluating
interindividual differences in susceptibility.
Thus, the public health value and use-
fulness of the bioassay for identifying
potential or likely human carcinogens has a
long history of being quite relevant and
predictive. Perhaps we should give more
attention to these laboratory results when
attempting to prevent human cancers
resulting from exposures to environmental
or occupational carcinogens (12).
James Huff
NIEHS
Research Triangle Park, North Carolina
E-mail: huffl@niehs.nih.gov
REFERENCES AND NOTES
1. Lewis DFV, loannides C, Parke DV. Cytochromes P450
and species differences in xenobiotic metabolism and
activation of carcinogen. Environ Health Perspect
106:633-641 (1998).
2. Huff JE. Value, validity, and historical development of
carcinogenesis studies for predicting and confirming
carcinogenic risks to humans. In: Testing, Predicting,
and Interpreting Chemical Carcinogenicity (Kitchin KT,
ed). NewYork:Marcel Dekker, 1999;21-123.
3. Fung VA, Barrett JC, Huff JE. The carcinogenesis
bioassay in perspective: application in identifying
human cancer hazards. Environ Health Perspect
103:680-683 (1995).
4. Huff JE. Carcinogenesis results in animals predict can-
cer risks to humans. In: Maxcy-Rosenau-Last Public
Health & Preventive Medicine (Wallace RB, ed). 14th
ed. Norwalk, CT:Appleton-Lange, 1998;543-550,
567-569.
5. Huff JE. Chemicals causally associated with cancers in
humans and in laboratory animals: a perfect concor-
dance. In: Carcinogenesis (Waalkes MP, Ward JM,
eds). NewYork:Raven Press,1994;25-37.
6. Tomatis L, Aitio A, Wilbourn J, Shuker L. Human car-
cinogens identified so far. Jpn J Cancer Res 80:795-807
(1989).
7. Tomatis L. The predictive value of rodent carcinogenic-
ity tests in the evaluation of human risks. Annu Rev
Pharmacol Toxicol 19:511-530(1979).
8. Huff J. Chemicals and cancer in humans: first evidence
in experimental animals. Environ Health Perspect
100:201-210 (1993).
9. Bucher JR, Portier CJ, Goodman JI, Faustman EM,
Lucier GW. Workshop overview. National Toxicology
Program studies: principles ofdose selection and appli-
cations to mechanistic based risk assessment. Fundam
Appi Toxicol 31:1-8 (1996).
10. Huff JE, Haseman JK, Rail DP. Scientific concepts,
value, and significance of chemical carcinogenesis
studies. Annu Rev Pharmacol Toxicol 31:621-652 (1991).
11. Bucher JR. Doses in rodent cancer studies: sorting fact
fromfiction. Drug Metab Rev(in press).
12. Tomatis L, Huff JE, Hertz-Picciotto I, Sandier D, Bucher
J, Boffetta P, Axelson 0, Blair A, Taylor J, Stayner L, et
al. Avoided and avoidable risks in cancer. Carcino-
genesis 18:97-105 (1997).
Coww
In the article by Ritz and Yu ('The
Effect ofAmbient.Carbon'Mobnoxide on
Low Birth. Wei.gbh:t amon.gChildren
Born n :Sou.ithern Californiabetwen
1989` and 1993") pulished in EHP
[107:17-25 (1999)], thei was..an error
in the second sen-tence of the
"Discussion. The satemet "the hemo-
globin in etal bood has 10 tim s more
affinity :for binding CC.)" sol:d read
"he he olbn in ftalbod has 10%t
mo)re affinity for binding CO."
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